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creativecommons.org/licenses/by-nc-nd/Abstract Background: The aim of this study was to quantify the impact of organised
mammography screening on breast cancer mortality across European regions. Therefore, a
systematic review was performed including different types of studies from all European re-
gions and stringently used clearly defined quality appraisal to summarise the best evidence.
Methods: Six databases were searched including Embase, Medline and Web of Science from
inception to March 2018. To identify all eligible studies which assessed the effect of organised
screening on breast cancer mortality, two reviewers independently applied predefined inclusion
and exclusion criteria. Original studies in English with a minimum follow-up of five years that
were randomised controlled trials (RCTs) or observational studies were included. The Co-
chrane risk of bias instrument and the NewcastleeOttawa Scale were used to assess the risk
of bias.
Results: Of the 5015 references initially retrieved, 60 were included in the final analysis. Those
comprised 36 cohort studies, 17 caseecontrol studies and 7 RCTs. None were from Eastern
Europe. The quality of the included studies varied: Nineteen of these studies were of very good
or good quality. Of those, the reduction in breast cancer mortality in attenders versus non-f Public Health, Erasmus MC, University Medical Center Rotterdam, Dr. Molewaterplein 40, Rotterdam,
mc.nl (N. Zielonke).
roup are listed in the supplementary material.
lished by Elsevier Ltd. This is an open access article under the CC BY-NC-ND license (http://
4.0/).
N. Zielonke et al. / European Journal of Cancer 127 (2020) 191e206192attenders ranged between 33% and 43% (Northern Europe), 43%e45% (Southern Europe) and
12%e58% (Western Europe). The estimates ranged between 4% and 31% in invited versus
non-invited.
Conclusion: This systematic review provides evidence that organised screening reduces breast
cancer mortality in all European regions where screening was implemented and monitored,
while quantification is still lacking for Eastern Europe. The wide range of estimates indicates
large differences in the evaluation designs between studies, rather than in the effectiveness of
screening.
ª 2019 The Authors. Published by Elsevier Ltd. This is an open access article under the CC
BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Breast cancer (BC) has become the most common cancer
in women worldwide in both developed and developing
countries [1,2]. Through early detection in asymptomatic
women, screening aims to reduce morbidity associated
with advanced stages of the disease, as well as cancer-
specific mortality. However, the benefits and harms of
mammography screening have been debated heatedly in
the last decades [3].
It is 35 years since randomised controlled trials (RCT)
showed that mammography screening leads to a reduc-
tion in BC mortality [4], which resulted in various policy
recommendations [5]. More recently, the effect of
running mammography screening outside the experi-
mental setting has been assessed. Several observational
studies have demonstrated that BC screening reduces BC
mortality [6e12]. However, screening has also harms.
After careful evaluation of the balance between the ben-
efits and adverse effects of mammography screening, the
most recent review by the International Agency for
Research on Cancer (IARC) concluded that there is a net
benefit from inviting women 50e69 years of age as well as
sufficient evidence for women up to 74 years of age to
receive screening [3].
At present, population-based BC screening pro-
grammes are ongoing, piloted or planned in 25 out of 28
European Union (EU) member states for nearly 95% of
women in the age group of 50e69 years [13]. BC screening
is delivered mainly by organised programmes encouraged
by theEuropeanCommission,which has publishedquality
assurance guidelines [14], which are currently being upda-
ted [15]. There is wide agreement on different aspects of the
screening policy, such as the screening test (mammog-
raphy), the minimum target age range (50e69 years) and
the screening interval (two years). On the other hand, there
are substantial differences within the European Union
(EU) in the extent to which target populations are actually
exposed to screening [16]. Currently there is nearly a two-
fold difference among the EU-countries in the coverage
by invitations and a more than five-fold difference in the
participation rate reported [17].
A considerable number of systematic reviews have
estimated the effectiveness of mammography screening in
terms of a reduction in BC mortality. Some of thesereviews included only RCTs [18e21], whereas others
focused exclusively on observational studies [8,11,12].
Several reviews did not follow a standardised quality
appraisal protocol [8,19,22,23]. These reviews demon-
strated high variability in estimates which led to different
conclusions and recommendations on the most appro-
priate screening strategy. Probably, the most extensive
and recent review was done for the IARC handbook.
Their average estimate was 40% reduction in the risk of
death from BC for women attending mammographic
screening [1]. However, to our knowledge, no review has
summarised the current evidence for all European re-
gions, including different types of studies, using a meth-
odologically sound quality appraisal. The aim of this
systematic review, therefore was to systematically eval-
uate and quantify the impact of organised screening on
BC-specific mortality across Europe.
The objective of this review is to answer the following
questions:
1. What is the impact of organised BC cancer screening on BC
mortality across Europe?
2. What are the differences between regions in Europe with
regards to BC mortality reduction due to screening?2. Methods
This systematic review was done in accordance with a
peer-reviewed protocol that is published and registered
with PROSPERO (CRD42016042433) [24]. We fol-
lowed the Preferred Reporting Items for Systematic
Reviews and Meta-Analyses (PRISMA) statement and
checklist when reporting our findings [25].
All methodological steps were performed by two in-
dependent reviewers (N.Z. and A.G.). Disagreement
between the two investigators were solved by consensus
or by consulting a third independent reviewer (E.E.L.J.).
2.1. Data sources and search
Based on our research questions, the Population,
Intervention, Control, Outcome, and Study design
(PICOS components), Table 1) served to define specific
keywords used in our comprehensive bibliographic
Table 1
PICOS criteria for inclusion and exclusion of studies.
Parameter Inclusion criteria Exclusion criteria
Population People invited to/participating in organiseda mass screening for
breast cancer in a European countryb
People from non-European countries.
Intervention Organised screening for breast cancer. Other screening interventions (e.g. breast self-examination)
Control People not invited to/not attending organised screening or people
participating in opportunistic screening only.
No control group (everybody is screened)
Outcome Change in breast cancer mortality due to screening. No direct estimation of breast cancer mortality reduction
due to screeningc
Study design Randomised controlled trials, retrospective and prospective
observational (cohort or caseecontrol) studies
Non-original research studies (e.g. editorials, letters, and
conference abstracts), modelling/simulation studies,
ecological studiesd.
a Based on the IARC Handbook of Cancer Prevention (2015) we defined organised screening as screening programmes organised at national or
regional level, with an explicit policy.
b Western Europe: Austria, Belgium, France, Germany, Ireland, Luxembourg, the Netherlands, United Kingdom and Switzerland. Northern
Europe: Denmark, Estonia, Faroe Islands, Finland, Iceland, Latvia, Lithuania, Norway and Sweden. Southern Europe: Cyprus, Gibralta,
Greece, Italy, Malta, Portugal, Spain. Eastern Europe: Bulgaria, Czech Republic, Croatia, Hungary, Poland, Romania, Slovakia, Slovenia.
c Studies that only provide estimates on changes of survival rates, were excluded.
d Ecological studies that simply compare trends between unmatched regions or single regions over time without statistical adjustments for e.g.
baseline risk, excluded.
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ducted on the Embase, Medline Ovid, Web of Science,
PubMed publisher, Google Scholar, and Cochrane Li-
brary. All databases were searched from inception to
March 2018. The computer-assisted searches were
designed and performed by a research librarian using
controlled keywords to assess the concepts related to
mammographic screening, BC and mortality among
European countries. In Appendix 1, the detailed search
strategies performed for every source are listed. To
augment the search and to improve the likelihood of
identifying studies that are only indexed in local jour-
nals, experts were asked to suggest additional articles
that were not retrieved through the above-mentioned
search strategy. Additional potentially eligible articles
were identified by hand searching the reference lists of
all included studies. The search was limited to articles
written in English conducted in any European country
and the authors only considered studies that included
data from RCTs or observational studies such as pro-
spective and retrospective controlled cohort or
caseecontrol studies. All references were managed in
Thomson Reuters Endnote X7.1, and duplicates were
removed.
2.2. Study selection
Two investigators independently reviewed the titles and
abstracts of all references identified by the literature
search by using the PICOS criteria displayed in Table 1.
Then all potentially suitable articles were reviewed in
depth and additional exclusions have been made
applying eligibility criteria proposed by Elmunzer and
colleagues [26]: (1) Studies in which data or patients
were duplicated in other manuscripts; (2) Studies in
which data were not reported for at least 5 years of
follow-up; (3) Studies in which the total number ofevents and participants were not reported for each study
group. If multiple studies compared the same region,
period or population, or reported on the same trial, the
study with the longest follow-up was retained. The full
texts of all included publications were screened for
eligibility. Relevant outcome data and study details such
as first author; year of publication; country where the
study was conducted; study design; screening target
population; follow-up information; sample size of the
study; assessment of confounding factors (such as
adjustment for self-selection bias), and the reported es-
timates (with corresponding 95% confidence intervals
[95%CI]) of the screening effect on BC mortality, were
extracted. Furthermore, eligible articles were grouped
according to European regions (Northern, Western,
Southern and Eastern Europe) following the classifica-
tion provided by the EUROVOC Multilingual
Thesaurus of the European Union [27].
2.3. Quality appraisal
We used the Cochrane risk of bias instrument [28] to
assess the quality of the included RCTs. This tool helps
to indicate the validity of the studies’ results and the
presence of any systematic error leading to an over-
estimation or underestimation of the true intervention
effect. The tool considers the risk of bias within five
domains, including randomised sequence generation,
allocation concealment, masking outcome assessors,
incomplete outcome data reporting and selective
outcome reporting. However, the sixth domain from the
original tool, masking of participants and personnel,
was not applied in this systematic review as it was
deemed not applicable to screening. The reviewers
judged each of the five domains and agreed in an overall
judgement for each study as low, moderate, or high risk
of bias.
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the NewcastleeOttawa Scale (NOS) [29]. Using the tool
with its specific questions for cohort studies and
caseecontrol studies respectively, each study is judged
on several items, categorised into three areas: the selec-
tion of the study groups, the comparability of the
groups, and the ascertainment of either the exposure or
outcome of interest. Originally, the NOS does not award
a point if the case definition of caseecontrol studies was
exclusively based on record linkage. However, many
studies on cancer screening are based on data from
cancer registries. As advocated in Anttila [30] cancer
registries can be held co-responsible for the quality and
impact assessment of screening programmes when
mandated and resourced adequately. Thus, when the
percentage of histologically verified cases of the respec-
tive cancer register was known to be above 95% ac-
cording to the IARC [31,32], we qualified the case
definition as independent validation and award a point
on this question. The highest quality studies are awar-
ded with a score of nine.
The risk of bias of studies included in this review has
been categorised as follows:Fig. 1. PRISMA flow chart of records through(I) Low risk RCTs,
(II) Moderate risk RCTs or score of 8 or 9 in observational
studies,
(III) High risk RCTs or score 5 to 7 in observational studies
and
(IV) Observational studies with a score from 0 to 4.3. Results
The PRISMA flowchart (Fig. 1) presents the number of
articles found and excluded in each stage. The initial
search retrieved a total of 6691 citations. The aug-
menting bibliographic search provided 153 additional
references. After removing duplicates, 5015 citations
were identified of which 150 potentially eligible articles
were selected for detailed full-text evaluation. After the
preliminary full-text analysis using the eligibility criteria
mentioned above, 89 references were excluded from our
review. A detailed overview of the reasons for exclusion
are presented in Appendix 3.
Of the 153 additional references from experts, 31 were
already identified by our initial literature search. The
remaining 122 studies were excluded mostly becausethe review searching and inclusion process.
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BC screening on cancer-specific mortality.
In total, 60 studies were included in the final in-depth
analysis. Those included 38 cohort studies [33e70], 17
caseecontrol studies [71e87] and 7 randomised controlled
trials [88e94]. Details of these studies and their main
characteristicse sortedbyEuropean regione are reported
in Table 2e4. Thirty studies were included for Northern
Europe [33e55,68,74,75,89e92,94]; 9 for SouthernEurope
[56e61,81,82,86]; and 22 studies for Western Europe
[62e67,69e73,76e80,83e85,87,88,93]. None of the
included studies came from Eastern Europe. The majority
of studies (51/60) covered the age group 50e69.
Considering the results of all 60 studies included in
this review, BC mortality reduction estimates for invited
versus non-invited women varied from 4% [89] to 36%
[90] in Northern Europe, from 25% [59,82] to 35% [56] in
Southern Europe and from 6% [66] to 47% [67] in
Western Europe. When comparing BC mortality of
screened versus non-screened women, estimates varied
from 2% [50] to 89% [38] in Northern Europe, from 43%
[86]to 67% [57] in Southern Europe and 12% [64] to 58%
[80] in Western Europe. Of the 60 included studies, 40
had statistically significant results.
3.1. European regions
The quality of the included studies was miscellaneous.
Among the 60 included reported results, 5% (3/60) fell
into quality category I, 27% (17/60) were graded as
quality category II, 60% (37/60) fell into category III
and 8% (5/60) into category IV. Due to the numerous-
ness of included studies, we will only highlight the re-
sults from those 19 studies from group I and II. The
estimated effect of organised mammographic screening
on BC-specific mortality from these studies, by Euro-
pean regions, is described in Fig. 2. The entirety of the
risk of bias assessment of all included cohort studies,
caseecontrol studies, and RCTs is displayed in
Appendix 4-6, respectively. Additionally, Appendix 7 is
a summary of the risk of bias assessment for the RCTs
used in this review.
3.2. North
A total of 30 studies were selected and reported for
Northern European countries, including Denmark,
Finland, Sweden, Norway and Iceland (Table 2). Five of
these references were randomised controlled trials, all
from Sweden, of which two were of low risk of bias and
one of moderate risk of bias. Two of the (very) good
studies establish the protective effect of being invited to
mammographic screening. Tabar (2011) [94] reports the
long-term effect of mammographic screening in the
Swedish Two-County trial. They found a highlysignificant reduction in BC mortality in women invited
to mammographic screening (RR Z 0.69 [95% CI:
0.56e0.84]), whereas the Malmo¨ mammographic
screening trial [89] initially did not find a statistically
significant effect of screening (RR Z 0.96 [95% CI:
0.68e1.35]) after a little less than 9 years of follow-up.
Andersson [90] provided additional follow-up data of
the two cohorts from the Malmo¨ Mammographic
Screening Trial, particularly for women between 45 and
50 years of age who were followed for an average of
10 years. They conclude that being invited to screening
lowers the BC mortality significantly (RR Z 0.64 [95%
CI: 0.45e0.89]). The reviewers appraised five of the 30
cohort studies from northern Europe to be of good
quality. Three come from Norway. The Norwegian BC
screening programme was initiated in 1996, when it
began as a pilot study in four of the 19 Norwegian
counties. The programme targets women aged 50 to 69
who are invited every 2 years. Olsen (2013) [48] observed
the change in BC mortality due to screening comparing
it to historical control groups in the four pilot study
counties, using an incidence-based approach. The
cohort study has a short follow-up of only 6 years and a
reported relative risk (RR) of 0.93 (0.77e1.12). Two
other reports included 15 years of follow-up. Weedon-
Fekjaer’s prospective cohort study estimated that invi-
tation to mammographic screening was associated with
a 28% reduced risk of death from BC compared with not
being invited (RR Z 0.72 [0.64e0.79]) [55]. Hofvind
(2013) [40] compared BC mortality of women attending
screening with that of a non-screened cohort, consid-
ering incidence-based mortality (IBM). Fifteen years
after the start of the programme, the reduction was
estimated to be 43% (RR Z 0.57 [0.51e0.64]). For
Copenhagen (Denmark), Olsen (2007) [49] analysed
IBM of women invited to the routine mammography by
linking screening registry, cancer registry, cause of death
registry, and population registry data for individual
women age 50e69. Using historical comparison groups,
the effect of invitation to mammography screening every
two years was as BC mortality reduction of 20%
(RR Z 0.80 [0.68e0.94]). Tabar et al. (2003) [54]
assessed the long-term effects (20 years) of mammo-
graphic service screening on BC mortality in two
Swedish counties for women aged 40e69 years. Taking
potential biases (e.g. age and self-selection bias) into
account, BC mortality of screened women was 41%
lower than that of unscreened women (RR Z 0.59
[0.53e0.66]).
Heina¨vaara (2016) [75] evaluated the long-term effect
of organised mammography screening on IBM in
Finland during 1992e2011 among 50e84-year-old
women using a caseecontrol design. The effect of
screening, corrected for self-selection bias, was 33%
(HR Z 0.67 [0.49e0.90]).
ble 2
aracteristics, risk of bias and results on breast cancer mortality of included studies, by quality score. Northern Europe.
udy Country Study
type
Participants Attendance Target age
(years)
Follow-up
(years)
Correction
for self-
selection
bias
Quality
scorea
Effect sizes for breast cancer mortality,
RR/HR/OR (95%CI)
Invited versus not invited Attenders versus
not attenders
ndersson I, 1988 Sweden RCT I:21,088,
C: 21,195
85% 45e79 9 n/a A RR Z 0.96 (0.68e1.35)
bar L., 2011 Sweden RCT I: 77,080, C: 55,985 85% 40e74 29 n/a A RR Z 0.69 (0.56e0.84)
ndersson I, 1997 Sweden RCT I: 13,528,
C: 12,242
NA <50 10 n/a B RR Z 0.64 (0.45e0.89)
eina¨vaara S, 2016 Finland Case-
control
Cases: 1,907 Controls: 18,978 86% 50e69 7.4 yes 8/9 HR Z 0.67 (0.49e0.90)
lsen AH, 2007 Denmark Cohort Participants: 430,823 pyr,
Non-participants: 634,224 pyrb
NA 50e69 10 n/a 8/9 RR Z 0.80 (0.68e0.94)
lsen AH, 2013 Norway Cohort Participants: 1,182,747 pyr,
Non-participants: 1,152,755 pyrb
NA 50e69 6 n/a 8/9 RR Z 0.93 (0.77e1.12)
bar L, 2003 Sweden Cohort Participants: 2.399,000 pyr,
Non-participants: 2,416,000 pyrb
85% 40e69 20 yes 8/9 RR Z 0.59 (0.53e0.66)
eedon-Fekjaer H, 2014 Norway Cohort Participants: 2,407,709 pyr,
Non-participants: 12,785,325 pyrb
76% 50e69 15 n/a 8/9 RR Z 0.72 (0.64e0.79)
ofvind S, 2013 Norway Cohort Participants: 4,184,060 pyr,
Non-participants: 988,641 pyrb
NA 50e69 15 yes 8/9 RR Z 0.57 (0.51e0.64)
urtsam N, 2016 Sweden RCT I: 21,904,
C: 30,31830.318
84% 39e59 14 n/a C RR Z 0.70 (0.53e0.93)
isell J, 1997 Sweden RCT I: 40,318,
C: 19,943
N/A 40e64 11.4 n/a C RR Z 0.74 (0.50e1.10)
nttila A, 2008 Finland Cohort s Participants: 89,893,
Non-participants: 68,862b
90% 50e59 15 n/a 7/9 Mortality rate 11.1%
(19.4e2.1)
nttinen A, 2006 Finland Cohort Participants: 552,
Non-participants: 341b
71% 50e69 8.0e12.5 n/a 7/9 HR Z 0.82 (0.59e1.12)
jor SH, 2015 Denmark Cohort Participants: 870,465 pyr,
Non-participants: 828,508 pyrb
NA 50e69 14 yes 7/9 RR Z 0.72 (0.59e0.87)
nttila A, 2002 Finland Cohort Participants: 161,400 Wy,
Non-participants: 155,400 Wyb
81.8% 50e59 8.5e10.5 n/a 6/9 RR Z 0.81 (0.62e1.05)
uffy SW, 2006 Sweden Cohort Participants: 566,423,
Non-participants: 542,187b
75% 40e69 >20 yes 6/9 RR Z 0.57 (0.53e0.62)
akama M, 1995 Finland Cohort Participants: 3,708
Non-participants: 6,223b
86% 40e47 9 no 6/9 RR Z 0.11 (0.00e0.71)
akama M, 1997 Finland Cohort Participants: 89,893,
Non-participants: 68,862b
85% 45e69 6 n/a 6/9 RR Z 0.76 (0.53e1.09)
nsson H, 2001 Sweden Cohort Participants: 162,986
Non-participants: 98,608
NA 50e69 10.6 n/a 6/9 RR Z 0.84 (0.67e1.05)
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Jonsson H, 2003 Sweden Cohort Participants: 43,749
Non-participants: 618,342
NA 40e64 22 n/a 6/9 RR Z 0.84 (0.67e1.05)
Jonsson H, 2003 Sweden Cohort Participants: 83,830,
Non-participants: 41,608
NA 70e74 10 n/a 6/9 RR Z 0.82 (0.57e1.19)
Kalager M, 2010 Norway Cohort Participants: 2,337,323 pyr,
Non-participants: 1,866,741 pyrb
NA 50e69 8 n/a 6/9 RR Z 0.90 (0.76e1.04)c
Parvinen I, 2006 Finland Cohort Participants: 963,362 pyr,
Non-participants: 1,016,664 pyrb
NA 55e69 15 n/a 6/9 Helsinki: RR Z 1.11 (0.95e1.29),
Tampere: RR Z 0.86 (0.65e1.12),
Turku: RR Z 0.64 (0.47e0.88)
Sarkeala T, 2008 Finland Cohort Participants: 1,439,753 pyr,
Non-participants: 34,803,524 pyr
NA 50e69 10 yes 6/9 RR Z 0.62 (0.43e0.85)
Tabar L, 2001 Sweden Cohort Participants: 1,100,931 pyr,
Non-participants: 1,213,136 pyrb
85% 40e69 30 yes 6/9 RR Z 0.50 (0.41e0.60) RR Z 0.52 (0.43e0.63)
Gabe R, 2007 Iceland Case-
control
Cases: 226,
Controls: 902b
61e68% 40e69 N/A yes 5/9 OR Z 0.65 (0.39e1.09)
Hellquist BN, 2011 Sweden Cohort Participants: 7,261,415,
Non-participants: 8,843,852
80e90% 40e49 16 no 5/9 RR Z 0.74 (0.66e0.83) RR Z 0.71 (0.62e0.80)
Jonsson H, 2000 Sweden Cohort Participants: 202,152
Non-participants: 237,279
NA 40e49 8 n/a 5/9 RR Z 0.91 (0.72e1.15)
Jonsson H, 2007 Sweden Cohort Participants: 109,000,
Non-participants: 77,000
NA 40e74 11 yes 5/9 RR Z 0.74 0.62e0.88)
Parvinen I, 2015 Finland Cohort Participants: 1,439,753 pyr,
Non-participants: 34,803,524 pyr
86.7 40e84 >10 n/a 5/9 TKU versus RoF: RR Z 0.85
(0.66e1.1)
TKU versus HEL: RR Z 0.75
(0.57e1.00)
BC Z Breast cancer, pyr Z person years, Wy Z Women years, OR Z Odds ratio; RR Z Relative risk; HR Z Hazard ratio; I: Intervention group; C: Control group; NA: not available; n/a: not
applicable; TKU: Turku, RoF: Rest of Finland, HEL: Helsinki, Target age: Ages targeted by the screening programme; Follow-up: Follow-up after initiation of the screening programme.
a Quality assessment made according to the NewcastleeOttawa scale and the Cochrane risk of bias instrument. Risk of bias for RCT was
categorised as follow: A (Low risk), B (Moderate risk) and C (High risk).
b Controls were drawn from the same population as the intervention group.
c this value was recomputed as RR from the results provided in the original article.
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Table 3
Characteristics, risk of bias and results on breast cancer mortality of included studies, by quality score. Southern Europe.
Study Country Study type Participants Attendance Target
age (years)
Follow-up
(years)
Correction for
self-selection
bias
Quality
scorea
Effect sizes for breast cancer mortality, RR/HR/OR (95%CI)
Invited versus not invited Attenders versus not attenders
Palli D, 1986 Italy Case-control Cases: 57,
Controls: 257b
NA 40e70 yes 8/9 OR Z 0.57
(0.35e0.89)
Puliti D, 2012 Italy Cohort study Participants: 32,544,
Non-participants: 18,552b
56% 50e69 16.5 yes 8/9 50-59: RR Z 0.55 (0.41e0.75),
60e69: RR Z 0.49 (0.38e0.64)
Barco I, 2015 Spain Cohort study Participants: 496,
Non-participants: 1,325b
NA 50e69 6 no 7/9 HR Z 0.33 (0.18e0.63)
Puliti D, 2008 Italy Case-control Cases: 2.371 (Exp: 297),
Controls: 9,484 (Exp: 1,718)b
n/a 50e74 n/a yes 7/9 OR Z 0.75 (0.62e0.92) OR Z 0.50 (0.42e0.60)
Paci E, 2002 Italy Cohort study Participants: 254,890 pyr,
Non-participants: 164,742 pyrb
NA 50e69 8 n/a 6/9 RR Z 0.75 (0.54e1.04)
Palli D, 1989 Italy Case-control Cases: 103 (Exp: 55),
Controls: 515 (Exp: 355)b
n/a 40-49, 50þ n/a 6/9 40-49: OR Z 0.63 (0.24e1.64),
50þ: OR Z 0.51 (0.29e0.89)
Ascunce EN, 2007 Spain Cohort study Participants: 185,
Non-participants: 123b
85% 50e69 14 n/a 5/9 RR Z 0.65 (0.51e0.82)
Paci E, 2005 Italy Cohort study Participants: 2,105,
Non-participants: 2,339b
NA 50e69 5 n/a 5/9 RR Z 0.73
(0.61e0.87)
BC Z Breast cancer, pyr Z person years, Wy Z Women years, OR Z Odds ratio; RR Z Relative risk; HR Z Hazard ratio; I: Intervention group; C: Control group; NA: not available; n/a: not
applicable; Target age: Ages targeted by the screening programme; Follow-up: Follow-up after initiation of the screening programme.
a Quality assessment made according to the NewcastleeOttawa scale and the Cochrane risk of bias instrument.
b Controls were drawn from the same population as the intervention group.
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Table 4
Characteristics, risk of bias and results on breast cancer mortality of included studies, by quality score. Western Europe.
Study Country Study type Participants Attendance Target age
(years)
Follow-up
(years)
Correction
for
self-selection
bias
Quality
scorea
Effect sizes for breast cancer mortality,
RR/HR/OR (95%CI)
Invited versus
not invited
Attenders versus not attenders
Moss S, 2015 UK RCT I: 53,883,
C: 106,953
81% 39e41 17 yes A RR Z 0.88 (0.74e1.04)
Johns LE, 2017 UK Cohort study Participants: 2,407,709 pyr,
Non-participants:
12,785,325 pyrc
74% 49e64 15 yes 9/9 RR Z 0.79
(0.73e0.84)
RR Z 0.68 (0.63e0.73)
Johns LE, 2017 UK Case-controlb Cases: 11,754 (Exp: 5,109)
Controls: 37,601 (Exp:
20,545) c
n/a 49e64 yes 9/9 OR Z 0.79
(0.71e0.88)
OR Z 0.53 (0.46e0.62)
Allgood PC, 2008 United Kingdom Case-control Cases: 284 (Exp: 208),
Controls: 568 (Exp: 505) c
n/a 50e70 yes 8/9 OR Z 0.65 (0.48e0.88)
Massat NJ, 2015 UK Case-control Cases: 391,
Controls: 417c
61.7% 47e89 yes 8/9 OR Z 0.69 (0.50e0.94)
Massat NJ, 2015 UK Case-control Cases: 869,
Controls: 1,642c
70.5e62.8% 47e89 yes 8/9 OR Z 0.61 (0.44e0.85)
Otto S, 2012 Netherlands Case-control Cases: 755,
Controls: 3,739c
79% 50e75 n/a yes 8/9 OR Z 0.51 (0.40e0.66)
Paap E, 2014 Netherlands Case-control Cases: 1,233,
Controls: 2,090
81.3% 50e75 n/a yes 8/9 OR Z 0.42 (0.33e0.53)
Alexander FE, 1999 United Kingdom RCT I: 28,628
C: 26,026
NA 45e65 14 no C RR Z 0.79 (0.60e1.02)
Broeders MJM, 2002 Netherlands Case-control Cases: 157 (Exp: 157),
Controls: 758 (Exp: 758) c
n/a 40e80 no 7/9 40-49: OR Z 0.90 (0.38e2.14),
50-59: OR Z 0.71 (0.35e1.46),
60-69: OR Z 0.80 (0.42e1.54)
Ernst M, 2004 Netherlands Cohort study Participants: 419,
Non-participants: 250c
NA 50e69 8 n/a 6/9 HR Z 0.75
(0.57e1.01)
Fielder HM, 2004 UK Case-control Cases: 419 (Exp: 275),
Controls: 717 (Exp: 535) c
n/a 50e75 yes 6/9 OR Z 0.75 (0.49e1.14)
Mook S, 2011 Netherlands Cohort study Participants: 958,
Non-participants: 1,634c
70e80% 50e69 10 no 6/9 HR Z 0.62 (0.50e0.86)
van Dijk JAAM, 1996 Netherlands Case-control Cases: 82 (Exp: 15),
Controls: 410 (Exp: 101) c
n/a 65þ n/a no 6/9 RR Z 0.56 (0.28e1.13)
Miltenburg GAJ, 1998 Netherlands Case-control Cases: 177 (Exp: 51),
Controls: 531 (Exp: 64) c
n/a 50e69 no 5/9 OR Z 0.54 (0.37e0.79)
Moss S, 1999 UK Cohort study Participants: 45,607,
Non-participants: 190,496
65e70% 45e64 16 no 5/9 RR Z 0.74 (0.63e0.86)
Sankatsing V, 2017 Netherlands Cohort study Participants: NA,
Non-participants: NAc
80% 50e74 13e20 n/a 5/9 % rate change
2010 compared
with 1980: 30
Otto SJ, 2003 Netherlands Cohort study Participants: 8,414,
Non-participants: 14,971c
NA 55e74 >10 n/a 4/9 % rate change
2001 compared
with 1986e1988:
19.9
(26.6 to 14.2)
(continued on next page)
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The characteristics of the nine included articles from
Southern European countries are reported in Table 3.
All selected studies were performed in Italy and Spain.
One caseecontrol study and one cohort study, both
from Florence/Italy, were judged to be of good quality
(category II). In a rural area near Florence a population-
based screening programme for BC was started in 1970.
The caseecontrol study by Palli (1986) [86] showed that
women who have been screened at least once had a BC
mortality reduction of 43% compared to women never
screened (OR Z 0.57 [0.35e0.89]). Puliti (2012) [61]
followed up women invited to the Florentine screening
programme every 2 years at age 50e69. Using an
incidence-based approach, the estimated mortality
reduction was 45% among 50- to 59-year-old women
(RR Z 0.55 [0.41e0.75]) and 51% among 60- to 69-
year-old women (RR Z 0.49 [0.38e0.64]) after
16 years of follow-up.
3.4. West
From Western European countries, the reviewers
included 22 studies which exclusively came from the
Netherlands and United Kingdom (Table 4). The UK
Age Trial (Moss, 2015) [93] was the only RCT from this
region that was judged to carry a low risk of bias.
However, it only refers to the specific group of women
aged 40e49 after 17 years of follow-up. Annual
mammography screening below age 50 leads to a rate
ratio (RR) for BC mortality of 0.88 (0.74e1.04). Six
caseecontrol studies reached a score of 8 or 9 (of 9), all
with fairly similar results: Allgood (2008) [71] performed
a study in the East Anglia region after the initiation of
the breast screening programme in 1989. The odds ratio
(OR) for death from BC in women who attend at least
one routine screen compared to those who did not
attend was 0.65 (0.48e0.88). Massat (2016) [76] assessed
the impact of the UK National Health Service breast
cancer Screening programme (NHS BSP) 20 years after
the inception and showed a BC mortality reduction of
39% among attenders (OR Z 0.61 [0.44e0.85]) In a
companion caseecontrol study, Massat (2016) [77] re-
ported that breast screening attendance reduces the fa-
tality risk by 31% (OR Z 0.69 [0.50e0.94]). A 47% BC
mortality reduction for attending women was found in a
nested caseecontrol study by Johns (2017) [87]
(OR Z 0.53 [0.46e0.62]), who evaluated the effective-
ness of the NHS breast screening programme in En-
gland and Wales. All of the British observational study
results were corrected for self-selection bias. For the
Netherlands, Paap (2014) [80] estimated the benefit of
the population-based screening programme to be as high
as 58% (ORZ 0.42 [0.33e0.53]) for screened compared
to unscreened women. Otto’s (2012) [79] assessment of
the effectiveness of mammography screening of Dutch
0.2 0.4 0.6 0.8 1 1.2 1.4
RR/ OR  breast cancer mortality reducƟon
Allgood PC, 2008, CC
John LE, 2017, CC
John LE, 2017, C
Massat NJ, 2015, CC
Massat NJ, 2015, CC
Moss S, 2015, RCT
OƩo S, 2012, CC
Paap E, 2014, CC
Andersson I, 1988, RCT
Andersson I, 1997, RCT
Heinävaara S, 2016, CC
Hofvind S, 2013, C
Olsen AH, 2007, C
Olsen AH, 2013, C
Tabar L, 2003, C
Tabar L., 2011, RCT
Weedon-Fekjaer H, 2014, C
Palli D, 1986, CC
PuliƟ D, 2012, (50-59) C
Fig. 2. Forest plot displaying the effectiveness of organised mammographic screening on breast cancer-specific mortality, of studies with
(very) good quality (group I and II), by European regions (Western Europe: diamond, Northern Europe: square, Southern Europe: circle).
The 95% confidence intervals for individual studies are represented by a horizontal line.
N. Zielonke et al. / European Journal of Cancer 127 (2020) 191e206 201women indicated a significant association between
attending mammography screening and risk of breast
cancer death (ORZ 0.51 [0.40e0.66]). Johns (2017) [70]
conducted the first individual-based cohort evaluation
of population breast screening in the UK, to estimate
the impact of the NHS breast screening programme
(NHS BSP) on BC mortality. After adjustment for self-
selection bias, the mortality reduction was 32%
(RR Z 0.68 [0.63e0.73]).
3.5. East
No studies from Eastern Europe met the inclusion
criteria.
4. Discussion
To the best of the authors’ knowledge, this review is the
first that comprises evidence from RCTs as well as
observational studies and stringently uses transparent
grading tools to appraise the quality of each included
reference and then highlights only those that provide the
most valid information. The results fortify that
mammography screening leads to reduced mortality
from BC, and the evaluation studies conducted in the
three European regions where screening was imple-
mented are confirming this conclusion.
The large number of possibly eligible studies for this
review as well as the number of other (systematic)reviews on this topic reflect the long history of evalua-
tions regarding the benefits of mammographic
screening, including some contrasting views.
In 2012, the Independent UK Panel on BC screening
relied mainly on findings from RCTs in order to pro-
vide estimates of the level of benefits and harms. Based
on 11 trials with 13 years of follow-up they concluded
that the relative risk reduction was 20% in women
invited for screening [19]. Gøtzsche and Jørgensen [21],
who included only RCTs in their review, found that the
trials with adequate randomisation did not find a sta-
tistically significant effect of screening on BC mortality.
Nevertheless, in the past decade concerns have been
raised about the applicability of RCTs in times of
growing availability of service screening and about the
validity of these trials. More recently, the evaluation of
screening benefits has shifted to population-based
screening services, and observational studies became
the main contributors of new information on the
impact of BC screening on BC mortality reduction [8].
Prerequisites for methodologically sound results there-
fore are individual data on screening exposure that is
sufficiently long (>5 years), reliable information on the
vital status as well as cancer data which can be directly
linked to a women’s screening history and to her cause
of death. The susceptibility to bias can furthermore be
limited when studies use incidence-based mortality
(IBM) and adjust for self-selection bias. By using
standardised tools to judge on the presence of all of
N. Zielonke et al. / European Journal of Cancer 127 (2020) 191e206202those methodological components, we were able to
identify those observational studies that are qualita-
tively consistent with well conducted RCTs. Of the 38
cohort studies included in this systematic review, 24
considered IBM and therewith only observed BC deaths
in women diagnosed after their first invitation to (or
attendance in) mammographic screening. In that way,
these studies only account for a risk of BC death at a
time, when it could have been affected by service
screening. BC mortality reductions were consistently
greater when the analysis compared screened versus
unscreened women rather than women who were
invited versus not invited to screening. All of the 17
caseecontrol studies included in this review compared
women attending in screening to non-attending ones.
The attractiveness of the caseecontrol approach is that
it uses observed mortality, and it requires fewer par-
ticipants than cohort studies. Thus it is a very efficient
tool to evaluate (new) organised screening programmes
[6,95]. However, non-compliers, those women who did
not accept the invitation to screening within organised
programmes, can potentially have a different risk of
death from BC than the general population. Therefore,
one major disadvantage of this study design is the
tendency to selection bias. Duffy et al. [9] provided a
method of adjustment for potential confounders. The
majority of the included caseecontrol studies adjusted
for self-selection bias. While most researchers agree that
the combination of both screening and treatment leads
to a reduction of BC mortality, some claim that the
reduction of BC mortality observed in Europe since the
1990s is mostly due to changes in cancer treatment [96].
Changes in treatment over time e in Norway, for
example, multidisciplinary breast care centres that have
been introduced parallelly with the organised screening
programme [40,46,97] - make the results difficult to
interpret. Both, caseecontrol or IBM studies implicitly
imply a treatment effect though. In order to disentangle
the synergistic effect of screening with better treatment
modelling analysis under different assumptions are
needed. In their simulation modelling study, Plevritis
et al. (2018) [98] evaluated the contributions associated
with screening and treatment to BC mortality re-
ductions for US women. The estimated reduction in BC
mortality rate between 2000 and 2012 was 49%, of
which 37% were associated with screening and 63%
with treatment, although the associations varied by BC
molecular subtype.
We discovered a lack of eligible studies from Eastern
Europe on mortality reduction due to screening. One
main explanation could be serious (financial) barriers to
organising and/or evaluating screening services [17].
Among the regions included in this study, some pop-
ulations had long-established screening programmes
running since the end of the 1980s (e.g. Finland) and
since the beginning of the 1990s (the Netherlands,Norway, Tuscany and Turin (Italy)) with complete
coverage of populations at screening age, but potentially
different age groups covered across these areas. Partic-
ularly for eastern European countries, opportunistic
screening has been offered to women since the early
1990s [99] and still plays an important role in explaining
low participation rates in the organised programmes
[17]. In most eastern European countries breast
screening programmes started more recently: Hungary
in 2001, Estonia in 2005, Lithuania in 2006, Cracow
(Poland) in 2007 and Slovenia in 2008. Hence a long
running monitoring and evaluation system is either still
missing or does not provide sound results yet.
This qualitative review is based on well-defined a
priori criteria and a rigorous systematic methodology.
Nonetheless, we note four potential limitations. First,
non-English-language studies were excluded. Second,
the large number of included studies and their meth-
odological designs led to a wide range of estimates of
mortality reduction due to screening. Therefore, we
did not aim for a meta-analysis and to synthesise the
results, but rather to highlight the reported evidence.
Three, we used very strict PICOS criteria during the
selection process following an in-depth quality assess-
ment through the Cochrane and NOS tools to limit
the risk of bias. While these choices may limit the
number of references that will be included in this
systematic review, it guarantees the best available ev-
idence on which we base the conclusions. Last, this
review did not include grey literature and thus solely
relies on published studies. Therefore, it might be
affected by publication bias, as published literature
appears to be predominantly biassed towards positive
results [100].
The variation in the point estimates from individual
studies indicates differences in evaluation designs, e.g.
in ages of follow-up of breast cancer incidence or
mortality, duration of follow-up since first invitation,
comparison group and assessment methods of self-
selection bias, rather than variability of the effective-
ness of screening. It would have been very important to
describe the patterns in more detail according to the
above factors, but it was often not possible yet, due to
lack of information provided in many studies. Recent
studies suggest that the impact can be highly variable,
depending upon, e.g. if breast cancers during screening
age only, or also after the last invitation round would
be included [75,101]. It would be very important to
assess the screening impacts after the whole life span
since the first invitation and describe the variable effects
in the various follow-up windows of relevance.
We prove that there are several methodologically
appropriate approaches that are able to capture the true
beneficial effect of mammographic screening. However,
in order to assess the validity of these results, future
reviews would strongly profit from quality appraisal
N. Zielonke et al. / European Journal of Cancer 127 (2020) 191e206 203tools which are specifically developed to judge the
impact of screening, as well as the quality of European
record linkage practice.
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